全球胺基醣苷類抗生素市場 - 2023-2030年

市場概況

全球胺基醣苷類抗生素市場在2022年達到16.364億美元，預計到2030年將出現有利可圖的增長，達到22.022億美元。在預測期內（2023-2030年），全球胺基醣苷類抗生素市場預計將呈現3.8%的複合增長率。

全球胺基醣苷類抗生素市場是製藥業中一個蓬勃發展的領域，主要是治療嚴重的細菌感染。胺基醣苷類抗生素是重要的抗生素，在醫院、診所和研究實驗室被廣泛利用。最近的市場趨勢顯示，對組合藥物的需求增加，以及對開發新配方的明顯重視。全球胺基醣苷類抗生素市場的重要發展包括研發計劃、監管部門的批准，以及在獸醫學中的應用不斷增加。

細菌感染日益普遍，老齡人口不斷增加，以及抗生素的大量使用是推動全球胺基醣苷類抗生素市場的因素。老年人口不斷增加，對胺基醣苷類抗生素的需求也在增加。根據世界衛生組織2022年的預測，全球60歲及以上的人口預計將急劇增長。到2030年，全世界每六個人中就有一個是60歲或以上的人，這個年齡組的人口估計將達到14億，而2020年是10億。

市場動態

結核病發病率的上升正在推動全球胺基醣苷類抗生素市場的增長。

結核病發病率的上升是推動全球胺基醣苷類抗生素市場大幅上升的主要因素之一。像氨基糖苷類的強效抗生素對於有效治療結核病這種嚴重的細菌性疾病是必要的。由於結核病發病率的上升，尤其是在發展中國家，對胺基醣苷類抗生素的需求正在增長。

例如，根據美國疾病控制和預防中心2023年的報告，在2022年，美國有8300個報告的結核病（TB）病例，促使每10萬人中有2.5個病例。這比2021年報告的7,874個病例有小幅上升。 2022年，結核病的發病率保持在每10萬人2.5例。

獸醫學中對氨基糖苷的需求不斷增長，推動了全球氨基糖苷市場的增長。

胺基醣苷類抗生素在獸醫學中的應用不斷擴大，為市場參與者提供了一個有利可圖的機會。在牲畜、伴侶動物和水產養殖中，胺基醣苷類抗生素通常被用來治療細菌感染。這些胺基醣苷類抗生素在家禽和豬業中以飼料和水的形式施用。

例如，支原體和大腸桿菌是促使家禽呼吸道感染的最常見原因，需要用胺基醣苷類抗生素治療。動物可以用胺基醣苷類抗生素治療大腸桿菌、變形桿菌、假單胞菌、沙門氏菌、志賀氏菌、沙雷特氏菌和腸桿菌等細菌感染。由於這些原因，獸藥在細菌感染中的使用將在預測期內推動全球胺基醣苷類抗生素市場的發展。

耐藥性的發展阻礙了全球胺基醣苷類抗生素市場的增長。

抗生素耐藥性是指細菌能夠耐受抗生素的作用，使其在治療細菌感染中失去作用。胺基醣苷類抗生素的長期和不適當使用促使了對這些抗生素有抗藥性的細菌菌株的發展，降低了它們的效率。

例如，耐甲氧西林金黃色葡萄球菌（MRSA）和產生長譜β-內酰胺酶（ESBL）的細菌正在對胺基醣苷類抗生素產生耐藥性。感染患者對胺基醣苷類抗生素的耐藥率、表型和機制都有報導。抗生素耐藥細菌，如MRSA和產ESBL的細菌，正在成為一個不斷上升的公共衛生威脅。

COVID-19的影響分析

COVID-19的爆發對全球胺基醣苷類抗生素行業產生了實質性影響。這場大流行擾亂了全球供應鏈，減少了包括胺基醣苷類抗生素行業在內的各種行業對商品和服務的需求。 COVID-19對胺基醣苷類抗生素市場最重要的影響之一是供應鏈的中斷，這促使了氨基糖苷類抗生素產量的下降。

這場大流行也增加了抗生素的使用，因為個人越來越關注自己的健康，並服用足夠的處方以避免感染和延長住院時間。然而，胺基醣苷類抗生素可能在抗擊COVID-19方面有特別的好處。根據國家醫學圖書館2021年發表的一篇論文，氨基糖苷類有可能成為SARS-CoV-2的抗病毒藥物。在體外，胺基醣苷類抗生素hygromycin B（hygB）和新黴素證明了對小鼠肝炎病毒（MHV）的抑制。還有人發現hygB對牛和貓的冠狀病毒有活性。

俄羅斯-烏克蘭衝突分析

俄羅斯和烏克蘭之間的衝突預計將對全球氨基糖苷市場產生實質性影響。因為戰區的傳染病發病率，促使了價格上漲，供應鏈中斷，以及對氨基糖苷的需求增加。據預測，這些因素將減少市場需求，提高價格，並擾亂供應鏈，使病人難以獲得基本的胺基醣苷類抗生素。

此外，衝突的間接影響，如較低的經濟增長和較低的醫療服務需求，可能促使市場的悲觀看法。雖然衝突的全部影響程度尚不清楚，但很明顯，全球胺基醣苷類抗生素行業將受到嚴重的影響。

目錄

第一章：方法和範圍

• 研究方法
• 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

• 按產品類型簡述
• 按給藥途徑分析
• 按應用分類
• 按地區分類

第四章：動態變化

• 影響因素
  • 驅動因素
    • 結核病發病率的上升推動了全球氨基糖苷市場的增長。
    • 氨基糖苷作為獸藥的需求不斷增長，推動了全球氨基糖苷市場的增長。
  • 限制因素
    • 耐藥性的發展阻礙了全球氨基糖苷市場的增長。
  • 機會
  • 影響分析

第五章：行業分析

• 波特五力分析
• 供應鏈分析
• 未滿足的需求
• 監管分析

第六章：COVID-19分析

• 對COVID-19的分析
  • COVID-19之前的情況
  • COVID-19期間的情況
  • COVID-19之後的情況
• 在COVID-19期間的定價動態
• 需求-供應譜系
• 大流行期間與市場有關的政府計劃
• 製造商的戰略計劃
• 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：按產品類型

• 新黴素
• 妥布黴素
• 慶大霉素
• 阿米卡星
• 副黴素
• 鏈黴素
• 卡那黴素
• 其他

第九章：按給藥途徑分類

• 注射劑
• 飼料
• 乳房內
• 外用
• 口服

第十章：按應用分類

• 獸醫
• 皮膚感染
• 呼吸系統疾病
• 尿毒症和盆腔疾病
• 其他疾病

第十一章：按地區分類

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 南美其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 亞太其他地區
• 中東和非洲

第十二章：競爭格局

• 競爭格局
• 產品標杆
• 公司佔有率分析
• 主要發展和戰略

第十三章：公司簡介

• Pfizer Inc.
  • 公司概述
  • 產品組合和描述
  • 財務概況
  • 主要發展情況
• Vega Pharma Ltd.
• Teva Pharmaceuticals USA, Inc.
• Huvepharma
• Cipla Limited
• Medson Pharmaceuticals
• Medico Remedies Pvt. Ltd
• Zoetis
• AstraZeneca
• Kremoint Pharma Pvt.

第十四章：附錄

Market Overview

The global aminoglycosides market reached US$ 1,636.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,202.2 million by 2030. The global aminoglycosides market is expected to exhibit a CAGR of 3.8% during the forecast period (2023-2030).

The global aminoglycosides market is a thriving sector in the pharmaceutical industry, focusing on the treatment of severe bacterial infections. Aminoglycosides are significant antibiotics that are widely utilized in hospitals, clinics, and research laboratories. Recent market trends reveal an increase in demand for combination medicines as well as a noticeable emphasis on developing novel formulations. Significant developments in the global aminoglycosides market include R&D initiatives, regulatory approvals, and a rising application in veterinary medicine.

The growing prevalence of bacterial infections, the increasing aging population, and high antibiotic usage are the factors driving the global aminoglycoside market. The growing geriatric population is increasing the demand for aminoglycoside drugs. According to WHO 2022 projection, the global population aged 60 and up is expected to grow dramatically. By 2030, one in every six individuals worldwide will be 60 or older, with the population in this age group estimated to reach 1.4 billion, up from 1 billion in 2020.

Market Dynamics

The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.

The rising incidence of tuberculosis is one of the main factors driving the significant rise of the global aminoglycoside market. Strong antibiotics like aminoglycosides are necessary for the efficient treatment of tuberculosis, a serious bacterial illness. The need for aminoglycosides is growing as a result of the rising prevalence of tuberculosis, particularly in developing nations.

For instance, according to the Centers for Disease Control and Prevention report of 2023, in 2022, there were 8,300 reported cases of tuberculosis (TB) in the United States, resulting in a rate of 2.5 cases per 100,000 people. This is a modest rise from the 7,874 cases reported in 2021. In 2022, the incidence of tuberculosis remained at 2.5 incidents per 100,000 people.

The Growing Demand for Aminoglycoside in Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market.

The use of aminoglycosides in veterinary medicine has been continuously expanding, offering market players a lucrative opportunity. In livestock, companion animals, and aquaculture, aminoglycosides are commonly used to treat bacterial infections. These aminoglycosides are administered in-feed and in-water form in poultry and pig industries.

For instance, Mycoplasma and Escherichia coli are the most frequent causes of respiratory infections in poultry that need to be treated with aminoglycosides. Animals can be treated with aminoglycosides for bacterial infections Escherichia coli, Proteus, Pseudomonas, Salmonella, Shigella, Serratia, and Enterobacter. Owing to these reasons, veterinary medicine usage in bacterial infection will drive the global aminoglycosides market over the forecast period.

The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.

Antibiotic resistance is the ability of bacteria to tolerate the effects of antibiotics, rendering them useless in treating bacterial infections. Prolonged and inappropriate usage of aminoglycosides has contributed to the development of bacterial strains resistant to these antibiotics, decreasing their efficiency.

For instance, Methicillin-resistant Staphylococcus aureus (MRSA) and bacteria producing extended-spectrum beta-lactamase (ESBL) are becoming resistant to aminoglycosides. Infected patients' aminoglycoside resistance rates, phenotypes, and mechanisms have all been reported. Antibiotic-resistant bacteria, such as MRSA and ESBL-producing bacteria, are becoming a rising public health threat.

COVID-19 Impact Analysis

The COVID-19 outbreak has had a substantial influence on the global aminoglycosides industry. The pandemic disrupted worldwide supply chains and reduced demand for goods and services in a variety of industries, including the aminoglycosides industry. One of the most significant effects of COVID-19 on the aminoglycosides market is the disruption of supply chains, which has resulted in a decline in aminoglycoside antibiotic production.

The pandemic has also increased antibiotic usage, as individuals are becoming more concerned about their health and taking adequate prescriptions to avoid infections and lengthier hospital stays. However, aminoglycosides may have particular benefits in the fight against COVID-19. According to a 2021 paper published by the National Library of Medicine, aminoglycosides have the potential to be SARS-CoV-2 antivirals. In vitro, inhibition of murine hepatitis virus (MHV) was demonstrated by the aminoglycosides hygromycin B (hygB) and neomycin. Others discovered hygB activity against bovine and feline coronaviruses.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine is expected to have a substantial influence on the global aminoglycoside market. Because of the incidence of infectious diseases in war zones, has led to higher pricing, supply chain interruptions, and increased demand for aminoglycosides. These factors are predicted to reduce market demand, raise prices, and disrupt the supply chain, making it difficult for patients to get essential aminoglycoside drugs.

Furthermore, the conflict's indirect effects, such as lower economic growth and lower demand for healthcare services, may contribute to the market's pessimistic view. While the full extent of the conflict's impact is unknown, it is clear that the global aminoglycosides industry will be severely impacted.

Segment Analysis

The global aminoglycosides market is segmented based on product type, route of administration, application, and region.

The Gentamicin Segment is expected to hold a Dominant Position for the Global Aminoglycoside Market over the Forecast Period.

The gentamicin segment accounted for the highest market share accounting for approximately 27.3% of the aminoglycoside market in 2022. Gentamicin is an antibiotic that is commonly used to treat severe bacterial infections in many regions of the body. It is the preferred treatment for serious infections, and its market expansion is being supported by expanded R&D.

A recent study conducted in 2022 and entitled "Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review" highlights the efficiency of a typical starting dose of 7 mg/kg based on total body weight in both adults and children older than one month, including critically ill patients. The likelihood of attaining the targeted treatment outcome is observed to be higher with this dosing technique. Thus, owing to the above factors, the market segment is expected to hold the largest market share for the global aminoglycoside market over the forecast period.

Geographical Analysis

North America holds a Dominant Position in the Global Aminoglycoside Market.

North America is estimated to hold around 36.9% of the total market share throughout the forecast period. The high disposable income, presence of major market players, an aging population, high prevalence of bacterial infections, and rising incidence of antibiotic resistance are some of the key factors expected to drive the aminoglycoside market in North America region over the forecast period.

The market for antibiotic formulations containing aminoglycosides is expanding significantly as a result of the involvement of several manufacturers in their creation. A significant milestone was reached by the U.S.-based company Padagis in March 2022 when the FDA gave the generic version of Tobradex ophthalmic suspension, which has an AB rating, the go-ahead. Tobramycin and dexamethasone make up this medication's active components.

Tobradex Ophthalmic Suspension is primarily used for the treatment of inflammatory, steroid-responsive ocular disorders where a corticosteroid is necessary, as well as when there is a risk of superficial bacterial ocular infection. Hence, owing to the above factors, the market is expected to drive over the forecast period

Competitive Landscape

The major global players in the market include: Pfizer Inc, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals. Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, and Kremoint Pharma Pvt. Ltd., among others.

Why Purchase the Report?

• To visualize the global aminoglycosides market segmentation based on the product type, route of administration, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aminoglycosides market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global aminoglycoside market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Application
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.
    • 4.1.1.2. The Growing Demand of Aminoglycoside as Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market
  • 4.1.2. Restraints
    • 4.1.2.1. The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Product Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.1.2. Market Attractiveness Index, By Product Type
• 8.2. Neomycin*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Tobramycin
• 8.4. Gentamicin
• 8.5. Amikacin
• 8.6. Paromomycin
• 8.7. Streptomycin
• 8.8. Kanamycin
• 8.9. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Injectables*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Feed
• 9.4. Intra-mammary
• 9.5. Topical
• 9.6. Oral

10. By Application

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.1.2. Market Attractiveness Index, By Application
• 10.2. Veterinary*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Skin Infection
• 10.4. Respiratory diseases
• 10.5. UTI & Pelvic Diseases
• 10.6. Other Diseases

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.6.1. The U.S.
    • 11.2.6.2. Canada
    • 11.2.6.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.6.1. Germany
    • 11.3.6.2. The U.K.
    • 11.3.6.3. France
    • 11.3.6.4. Italy
    • 11.3.6.5. Spain
    • 11.3.6.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.6.1. Brazil
    • 11.4.6.2. Argentina
    • 11.4.6.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.6.1. China
    • 11.5.6.2. India
    • 11.5.6.3. Japan
    • 11.5.6.4. Australia
    • 11.5.6.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Product Benchmarking
• 12.3. Company Share Analysis
• 12.4. Key Developments and Strategies

13. Company Profiles

• 13.1. Pfizer Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Vega Pharma Ltd.
• 13.3. Teva Pharmaceuticals USA, Inc.
• 13.4. Huvepharma
• 13.5. Cipla Limited
• 13.6. Medson Pharmaceuticals
• 13.7. Medico Remedies Pvt. Ltd
• 13.8. Zoetis
• 13.9. AstraZeneca
• 13.10. Kremoint Pharma Pvt.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us